Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831.
作者信息
Kaul Sanjay
出版信息
Diabetes Care. 2018 Mar;41(3):640. doi: 10.2337/dc18-er03a. Epub 2018 Jan 8.
Abstract
摘要
相似文献
1
Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831.
Diabetes Care. 2018 Mar;41(3):640. doi: 10.2337/dc18-er03a. Epub 2018 Jan 8.
2
Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831.对考尔的评论。使用抗糖尿病药物降低2型糖尿病患者的心血管风险：对EMPA-REG OUTCOME、LEADER和SUSTAIN-6试验主要心血管结局结果的综述。《糖尿病护理》2017年；40:821 - 831。
Diabetes Care. 2017 Dec;40(12):e174. doi: 10.2337/dc17-1527.
3
Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831.对关于考尔的评论的回应。使用抗糖尿病药物减轻2型糖尿病患者的心血管风险：对EMPA-REG OUTCOME、LEADER和SUSTAIN-6试验主要心血管结局结果的综述。《糖尿病护理》2017年；40:821 - 831。
Diabetes Care. 2017 Dec;40(12):e175-e176. doi: 10.2337/dci17-0044.
4
5
Cardiovascular Outcome Trials in Diabetes: Will the EMPA-REG OUTCOME and LEADER Trials Influence Clinical Decisions in Type 2 Diabetes?糖尿病心血管结局试验：依帕列净治疗心血管结局研究（EMPA-REG OUTCOME）和利拉鲁肽治疗2型糖尿病（LEADER）试验会影响2型糖尿病的临床决策吗？
Can J Diabetes. 2016 Oct;40(5):379-381. doi: 10.1016/j.jcjd.2016.08.220.
6
After EMPA-REG OUTCOME and LEADER: Already a "New Era" in Therapy of Type 2 Diabetes?
Exp Clin Endocrinol Diabetes. 2016 Sep;124(8):459-460. doi: 10.1055/s-0042-111316. Epub 2016 Oct 4.
7
[Cardiovascular protection of patients with type 2 diabetes : from EMPA-REG OUTCOME to LEADER].2型糖尿病患者的心血管保护：从恩格列净心血管结局研究到利拉鲁肽心血管和降低死亡率研究
Rev Med Suisse. 2016 Aug 24;12(527):1370-1375.
8
Impact of EMPA-REG OUTCOME on the management of type 2 diabetes mellitus: a review for primary care physicians.恩格列净心血管结局研究（EMPA-REG OUTCOME）对2型糖尿病管理的影响：基层医疗医生综述
Postgrad Med. 2016 Nov;128(8):822-827. doi: 10.1080/00325481.2016.1245093. Epub 2016 Oct 25.
9
EMPA-REG OUTCOME: The Endocrinologist's Point of View.恩格列净心血管结局研究（EMPA-REG OUTCOME）：内分泌科医生的观点
Am J Med. 2017 Jun;130(6S):S51-S56. doi: 10.1016/j.amjmed.2017.04.005.
10
Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.降低血压对2型糖尿病患者肾脏结局的影响：聚焦于钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂和恩格列净心血管结局研究（EMPA-REG OUTCOME）
Diabetes Metab. 2017 Apr;43(2):99-109. doi: 10.1016/j.diabet.2016.12.010. Epub 2017 Jan 30.
Zotero 插件